You are here: Industry Insights > hyperkalaemia

News List

AstraZeneca’s Lokelma approved for hyperkalaemia in Japan pharmaceutical-technology
March 27, 2020
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) for patients with hyperkalaemia, characterised by elevated levels of potassium in the blood.
Treatment for hyperkalaemia recommended by NICE for NHS europeanpharmaceuticalreview
December 19, 2019
NICE has recommended patients in England have access to a new treatment option for treating hyperkalaemia (raised serum potassium levels) in adults.
NICE recommends Lokelma treatment for hyperkalaemia europeanpharmaceuticalreview
August 05, 2019
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
Positive results for AZ’ Lokelma in hyperkalaemia pharmatimes
June 18, 2019
AstraZeneca has announced a statistically significant and clinically meaningful improvement from its Phase IIIb DIALIZE trial, investigating the efficacy and safety of Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia in patients
EU approves AZ’ potassium binder for hyperkalaemia pharmatimes
July 20, 2018
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
FDA approves AZ's Lokelma for hyperkalaemia pharmafile
May 25, 2018
The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia.
AstraZeneca Receives Complete Response Letter from FDA for ZS-9 for Hyperkalaemia americanpharmaceuticalreview
March 20, 2017
AstraZeneca announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate).
AstraZeneca’s hyperkalaemia treatment rebounds with European recommendation pharmafile
February 27, 2017
AstraZeneca have received some positive news on its hyperkalaemia drug, ZS-9, as it received a recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the EMA.